SUBSCRIBE
SUBSCRIBE

Cingulate Therapeutics

NEWS
Drug Development
Clinical Catch-Up: 3’s the Charm for Pfizer-BioNTech Vaccine in Kids & More
A roundup of last week’s top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
May 27, 2022
 · 
10 min read
 · 
Mark Terry
Bio NC
Anxious? Activate Your Anterior Cingulate Cortex With a Little Meditation, Wake Forest University Baptist Medical Center Study
June 5, 2013
 · 
1 min read
JOBS
IN THE PRESS
Press Releases
Final Study Completed for Cingulate’s Lead Asset CTx-1301
January 7, 2025
 · 
7 min read
Press Releases
Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000
December 23, 2024
 · 
3 min read
Press Releases
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
November 8, 2024
 · 
7 min read
Press Releases
Cingulate Announces Adjournment of Special Meeting
October 10, 2024
 · 
2 min read
Press Releases
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
September 12, 2024
 · 
6 min read
Business
Cingulate to Participate in Benzinga All Live Access Event
August 27, 2024
 · 
1 min read
Press Releases
Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD
August 15, 2024
 · 
5 min read
Press Releases
Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved
August 13, 2024
 · 
9 min read
Drug Development
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD
May 21, 2024
 · 
8 min read
Business
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
May 8, 2024
 · 
6 min read
Load More